ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

VCEL Vericel Corporation

47.70
-0.48 (-1.00%)
May 31 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 200,341
Bid Price 43.88
Ask Price 55.80
News -
Day High 49.0945

Low
30.18

52 Week Range

High
53.05

Day Low 46.96
Company Name Stock Ticker Symbol Market Type
Vericel Corporation VCEL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.48 -1.00% 47.70 20:00:00
Open Price Low Price High Price Close Price Prev Close
48.64 46.96 49.0945 47.70 48.18
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,991 200,341 $ 47.83 $ 9,582,709 - 30.18 - 53.05
Last Trade Time Type Quantity Stock Price Currency
16:20:00 priorref 139 $ 47.70 USD

Vericel Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
2.3B 48.29M - 197.52M -3.18M -0.07 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Vericel News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No VCEL Message Board. Create One! See More Posts on VCEL Message Board See More Message Board Posts

Historical VCEL Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week48.3349.094546.4947.74297,629-0.63-1.30%
1 Month48.8751.9645.4748.58371,030-1.17-2.39%
3 Months45.3153.0542.37547.76407,1482.395.27%
6 Months35.5453.0532.3142.99478,65012.1634.21%
1 Year33.0353.0530.1839.46414,26114.6744.41%
3 Years56.5068.9417.3036.36423,339-8.80-15.58%
5 Years15.1668.946.7831.02500,26532.54214.64%

Vericel Description

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.